Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-01-26
2010-12-07
Hill, Kevin K. (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100
Reexamination Certificate
active
07846720
ABSTRACT:
One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids). This new plasmid comprises a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, a selectable marker gene sequence, and an improved origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.
REFERENCES:
patent: 4822470 (1989-04-01), Chang
patent: 4970154 (1990-11-01), Chang
patent: 5061690 (1991-10-01), Kann et al.
patent: 5134120 (1992-07-01), Boyd et al.
patent: 5292721 (1994-03-01), Boyd et al.
patent: 5298422 (1994-03-01), Schwartz et al.
patent: 5304486 (1994-04-01), Chang
patent: 5364791 (1994-11-01), Vegeto et al.
patent: 5374544 (1994-12-01), Schwartz et al.
patent: 5756264 (1998-05-01), Schwartz et al.
patent: 5874534 (1999-02-01), Vegeto et al.
patent: 5925564 (1999-07-01), Schwartz et al.
patent: 5935934 (1999-08-01), Vegeto et al.
patent: 6040295 (2000-03-01), Rolland et al.
patent: 6114148 (2000-09-01), Seed et al.
patent: 6410228 (2002-06-01), Schwartz et al.
patent: 6423693 (2002-07-01), Schwartz et al.
patent: 6551996 (2003-04-01), Schwartz et al.
patent: 7316925 (2008-01-01), Draghia-Akli et al.
patent: 2003/0074679 (2003-04-01), Schwartz et al.
patent: 2003/0157717 (2003-08-01), Draghia-Akli
patent: 2004/0014645 (2004-01-01), Draghia-Akli et al.
patent: 2004/0038918 (2004-02-01), Draghia-Akli et al.
patent: 2004/0057941 (2004-03-01), Draghia-Akli et al.
patent: 2004/0092009 (2004-05-01), Draghia-Akli et al.
patent: 2004/0138111 (2004-07-01), Draghia-Akli et al.
patent: 2004/0167458 (2004-08-01), Draghia-Akli et al.
patent: 2004/0175727 (2004-09-01), Draghia-Akli et al.
patent: 2004/0192593 (2004-09-01), Draghia-Akli et al.
patent: 2004/0204358 (2004-10-01), Brown et al.
patent: 2005/0004060 (2005-01-01), Draghia-Akli et al.
patent: 2005/0014245 (2005-01-01), Hebel et al.
patent: 2005/0032737 (2005-02-01), Draghia-Akli
patent: 2005/0052630 (2005-03-01), Smith et al.
patent: 2005/0171046 (2005-08-01), Draghia-Akli et al.
patent: 2005/0182014 (2005-08-01), Draghia-Akli et al.
patent: 2005/0238624 (2005-10-01), Rabinovsky et al.
patent: 2006/0025368 (2006-02-01), Draghia-Akli et al.
patent: 772752 (2001-02-01), None
patent: 200197157 (2002-02-01), None
CVU47122, 1996.
1994, AAA52609.
Seyfang et al, Analy. Biochem. 324:285-291, 2004.
U.S. Appl. No. 60/590,739, filed Jul. 23, 2004, Draghia-Akli et al.
Acsadi G, Dickson G, Love DR, Jani A, Walsh FS, Gurusinghe A, Wolff JA, Davies KE. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature. Aug. 29, 1991;352(6338):757-8.
Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. Jun. 1999;17(6):517.
Almendro N, Bellon T, Rius C, Lastres P, Langa C, Corbi A, Bernabeu C. Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J Immunol. Dec. 15, 1996;157(12):5411-21.
Aratani Y, Okazaki R, Koyama H. End extension repair of introduced targeting vectors mediated by homologous recombination in mammalian cells. Nucleic Acids Res. Sep. 25, 1992;20(18):4795-801.
Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine. Jan. 30, 2003;21(7-8):649-58.
Bert AG, Burrows J, Osborne CS, Cockerill PN. Generation of an improved luciferase reporter gene plasmid that employs a novel mechanism for high-copy replication. Plasmid. Sep. 2000;44(2):173-82.
Bettan M, Emmanuel F, Darteil R, Caillaud JM, Soubrier F, Delaere P, Branelec D, Mahfoudi A, Duverger N, Scherman D. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther. Sep. 2000;2(3):204-10.
Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell. Jun. 1985;41(2):521-30.
Brown PA, Davis WC, Draghia-Akli R. Immune-enhancing effects of growth hormone-releasing hormone delivered by plasmid injection and electroporation. Mol Ther. Oct. 2004;10(4):644-51.
Bujard H, Baldari C, Brunner M, Deuschle U, Gentz R, Hughes J, Kammerer W, Stuber D. Integration of efficient promoters of theE. colisystem into plasmid vectors. Gene Amplif Anal. 1983;3:65-87.
Carbonelli DL, Corley E, Seigelchifer M, Zorzopulos J. A plasmid vector for isolation of strong promoters inEscherichia coli. FEMS Microbiol Lett. Aug. 1, 1999;177(1):75-82.
Chandler SD, Mayeda A, Yeakley JM, Krainer AR, Fu XD RNA splicing specificity determined by the coordinated action of RNA recognition motifs in SR proteins. Proc Natl Acad Sci U S A. Apr. 15, 1997;94(8):3596-601.
Cocea L. Duplication of a region in the multiple cloning site of a plasmid vector to enhance cloning-mediated addition of restriction sites to a DNA fragment. Biotechniques. Nov. 1997;23(5):814-6.
Dai B, Wu H, Holthuizen E, Singh P. Identification of a novel cis element required for cell density-dependent down-regulation of insulin-like growth factor-2 P3 promoter activity in Caco2 cells. J Biol Chem. Mar. 9, 2001;276(10):6937-44. Epub Dec. 8, 2000.
Danko I, Wolff JA. Direct gene transfer into muscle. Vaccine. Dec. 1994;12(16):1499-502.
Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. Dec. 1997;4(12):1341-9.
Darquet AM, Rangara R, Kreiss P, Schwartz B, Naimi S, Delaere P, Crouzet J, Scherman Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. Feb. 1999;6(2):209-18.
Dasgupta S, Masukata H, Tomizawa J. Multiple mechanisms for initiation of ColE1 DNA replication: DNA synthesis in the presence and absence of ribonuclease H. EMBO J. Nov. 1986;5(11):2987-94.
Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum Gene Ther. Apr. 1993;4(2):151-9.
Deuschle U, Kammerer W, Gentz R, Bujard H. Promoters ofEscherichia coli: a hierarchy of in vivo strength indicates alternate structures. EMBO J. Nov. 1986;5(11):2987-94.
Dolnik V, Novotny M, Chmelik J. Electromigration behavior of poly-(L-glutamate) conformers in concentrated polyacrylamide gels. Biopolymers. Aug. 1993;33(8):1299-306.
Dorsch-Hasler K, Keil GM, Weber F, Jasin M. Schaffner W, Koszinowski UH. A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A. Dec. 1985;82(24):8325-9.
Draghia-Akli R, Ellis KM, Hill LA, Malone PB, Fiorotto ML. High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J. Mar. 2003;17(3):526-8. Epub Jan. 2, 2003.
Draghia-Akli R, Fiorotto ML, Hill LA, Malone PB, Deaver DR, Schwartz RJ. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol Dec. 1999;17(12):1179-83.
Draghia-Akli R, Khan AS, Cummings KK, Parghi D, Carpenter RH, Brown PA. Electrical enhancement of formulated plasmid delivery in animals. Technol Cancer Re
Draghia-Akli Ruxandra
Pope Melissa
Hill Kevin K.
Kim Thomas
VGX Pharmaceuticals, Inc.
LandOfFree
Optimized high yield synthetic plasmids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optimized high yield synthetic plasmids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optimized high yield synthetic plasmids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196557